Jubilant Pharmova Q2 Results: EBITDA Shines, But Should You Hold or Fold? A 360° Analysis
Jubilant Pharmova’s Q2 FY24 Report Card: A Tale of Operational Grit The Indian stock market witnessed a nuanced performance from Jubilant Pharmova Ltd. as it unveiled its financial results for the second quarter of fiscal year 2024 (Q2 FY24). For investors tracking the pharma space, the numbers presented a classic case of ‘good in parts’. […]